Advertisement

Topics

LMI - Ablavar - 401 - Study of Incidence of Nephrogenic Systemic Fibrosis(NSF) in Kidney Disease Patients Undergoing MRI With Ablavar

2014-08-27 03:13:15 | BioPortfolio

Summary

Study Design:

In this phase 4 study, all patients will receive 1 dose of Ablavar as part of an MRI examination in their routine clinical management.

A standardized NSF questionnaire will be administered to the patient at various time points post-dose. At 1 year and 2 years (+1 or -1 month) patients will return to the clinic for a limited examination for skin abnormalities and formal review of signs and symptoms suggestive of NSF.

Description

Study Design:

This Phase 4, open-label, two-year, prospective, multi-center, follow-up study will be conducted in up to 15 active sites in the United States.

All patients will receive 1 dose of Ablavar as part of an MRI examination in their routine clinical management. Prior to undergoing an Ablavar MRI, patients will have a baseline serum creatinine test within 24 hours prior to Ablavar administration, will sign an Informed Consent (IC) form, and will undergo a brief medical history assessment on the day of and prior to Ablavar administration.

A standardized NSF questionnaire will be administered to the patient at 48 (+ or -12) hours, 1 month (+ or - 1 week), 3 months (+ or - 2 weeks), 6 (+ or - 1) months, and 18 (+ or - 1) months post-dose. At 12 (+ or - 1) months, and at 24 (+ or - 1) months, patients will return to the clinic for a limited examination for skin abnormalities and formal review of signs and symptoms suggestive of NSF.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Conditions

Nephrogenic Systemic Fibrosis

Intervention

Ablavar

Location

Mennitt - Weill Cornell Medical College
New York
New York
United States
10065

Status

Not yet recruiting

Source

Lantheus Medical Imaging

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:13:15-0400

Clinical Trials [1145 Associated Clinical Trials listed on BioPortfolio]

Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec

The investigators will study the effect of imatinib mesylate (Glivec) in treatment of moderate to severe nephrogenic systemic fibrosis (NSF). So far there is no evidence of adequately eff...

Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection

The objective of this study is to prospectively monitor the incidence of adverse drug reactions, specifically NSF during routine use of gadoversetamide in a large number of patients with m...

Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels

The primary objective of this study is to determine any causative or associated factors contributing to the development of Nephrogenic Systemic Fibrosis (NSF), Nephrogenic Fibrosing Dermop...

Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants

The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed whil...

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Renal Insufficiency After the Administration of Magnevist

Assess potential risk for NSF in subjects with renal impairment (moderate/severe) post magnevist injection. Subjects will be screened with in 48 hours of previously scheduled MRI, those m...

PubMed Articles [4430 Associated PubMed Articles listed on BioPortfolio]

10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016.

The aim of this study was to critically assess the evaluation and categorization process for nephrogenic systemic fibrosis (NSF) based on reports received by Bayer from 2006 to 2016.

Letter on 'European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis'.

We read with interest the guidelines recently published on sclerosing diseases of the skin (Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis)[1, 2]. However, we are concerned that ...

MR Imaging and Gadolinium: Reassessing the Risk of Nephrogenic Systemic Fibrosis in Patients with Severe Renal Disease.

Cardiac Magnetic Resonance Imaging of the Myocardium in Chronic Kidney Disease.

Early stages of chronic kidney disease (CKD) are often underdiagnosed, while their deleterious effects on the cardiovascular (CV) system are already at work. Thus, the assessment of early CV damage is...

Repression of Adipose Tissue Fibrosis through a PRDM16-GTF2IRD1 Complex Improves Systemic Glucose Homeostasis.

Adipose tissue fibrosis is a hallmark of malfunction that is linked to insulin resistance and type 2 diabetes; however, what regulates this process remains unclear. Here we show that the PRDM16 transc...

Medical and Biotech [MESH] Definitions

A chronic, acquired, idiopathic, progressive eruption of the skin that occurs in the context of RENAL FAILURE. It is sometimes accompanied by systemic fibrosis. The pathogenesis seems to be multifactorial, with postulated involvement of circulating fibrocytes. There is a strong association between this disorder and the use of gadolinium-based contrast agents.

Irreversible FIBROSIS of the submucosal tissue of the MOUTH.

An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands.

An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.

A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)

More From BioPortfolio on "LMI - Ablavar - 401 - Study of Incidence of Nephrogenic Systemic Fibrosis(NSF) in Kidney Disease Patients Undergoing MRI With Ablavar"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Radiology
Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...


Searches Linking to this Trial